Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $7.57 Consensus PT from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned a consensus rating of "Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $7.57.

Several brokerages recently weighed in on TSHA. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Citigroup reissued an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday, April 28th. JMP Securities lifted their price objective on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Finally, Chardan Capital boosted their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, May 29th.

Taysha Gene Therapies Trading Up 0.8%

Shares of Taysha Gene Therapies stock traded up $0.02 during trading on Thursday, hitting $2.57. The company's stock had a trading volume of 3,282,567 shares, compared to its average volume of 3,048,919. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.35 and a quick ratio of 5.35. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $3.31. The stock has a market cap of $551.68 million, a price-to-earnings ratio of -7.56 and a beta of 1.04. The stock has a 50-day moving average price of $2.26 and a two-hundred day moving average price of $1.92.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative return on equity of 104.93%. The company had revenue of $2.30 million for the quarter, compared to analysts' expectations of $1.48 million. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. Equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 750,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, May 30th. The stock was bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the purchase, the insider now directly owns 2,841,704 shares in the company, valued at approximately $7,814,686. This represents a 35.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.78% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Granahan Investment Management LLC grew its position in Taysha Gene Therapies by 0.3% in the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after purchasing an additional 4,412 shares during the period. Hsbc Holdings PLC increased its stake in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock valued at $55,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC increased its stake in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after purchasing an additional 11,390 shares in the last quarter. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.